Canal Capital Management’s AbbVie ABBV Stock Holding History

Canal Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.23M	Buy	4,890 +10	+0.2%	+$2.15K	0.15%	91
2026 Q1	$1.06M	Sell	4,880 -43	-0.9%	-$9.54K	0.14%	89
2025 Q4	$1.12M	Buy	4,923 +10	+0.2%	+$2.28K	0.16%	81
2025 Q3	$1.14M	Sell	4,913 -666	-12%	-$136K	0.17%	77
2025 Q2	$1.04M	Buy	5,579 +151	+3%	+$28.1K	0.16%	81
2025 Q1	$1.14M	Sell	5,428 -24,378	-82%	-$4.74M	0.19%	75
2024 Q4	$5.3M	Sell	29,806 -1,113	-4%	-$205K	0.86%	34
2024 Q3	$6.11M	Buy	30,919 +317	+1%	+$59.2K	0.98%	34
2024 Q2	$5.25M	Buy	30,602 +958	+3%	+$159K	0.9%	38
2024 Q1	$5.4M	Buy	29,644 +2,886	+11%	+$497K	0.91%	39
2023 Q4	$4.15M	Buy	26,758 +2,198	+9%	+$320K	0.77%	39
2023 Q3	$3.66M	Buy	24,560 +704	+3%	+$103K	0.75%	41
2023 Q2	$3.21M	Buy	23,856 +1,364	+6%	+$200K	0.65%	44
2023 Q1	$3.58M	Buy	22,492 +15,041	+202%	+$2.3M	0.79%	37
2022 Q4	$1.2M	Buy	7,451 +180	+2%	+$27.6K	0.29%	72
2022 Q3	$976K	Buy	7,271 +24	+0.3%	+$3.44K	0.28%	69
2022 Q2	$1.11M	Buy	7,247 +63	+0.9%	+$9.63K	0.33%	65
2022 Q1	$1.17M	Sell	7,184 -44	-0.6%	-$6.39K	0.31%	65
2021 Q4	$979K	Buy	7,228 +56	+0.8%	+$6.62K	0.24%	72
2021 Q3	$774K	Sell	7,172 -18	-0.3%	-$2.06K	0.22%	75
2021 Q2	$810K	Buy	7,190 +422	+6%	+$47.5K	0.23%	76
2021 Q1	$732K	Sell	6,768 -21	-0.3%	-$2.25K	0.25%	78
2020 Q4	$727K	Buy	6,789 +325	+5%	+$31.2K	0.27%	76
2020 Q3	$566K	Sell	6,464 -87	-1%	-$8.19K	0.25%	81
2020 Q2	$643K	Buy	6,551 +196	+3%	+$17.3K	0.31%	72
2020 Q1	$484K	Buy	6,355 +2,183	+52%	+$186K	0.27%	75
2019 Q4	$369K	Sell	4,172 -563	-12%	-$46.7K	0.19%	87
2019 Q3	$359K	Sell	4,735 -208	-4%	-$14.3K	0.22%	89
2019 Q2	$359K	Sell	4,943 -16,591	-77%	-$1.3M	0.22%	85
2019 Q1	$1.74M	Buy	21,534 +693	+3%	+$56.7K	1.1%	31
2018 Q4	$1.92M	Buy	20,841 +1,003	+5%	+$88.2K	1.3%	22
2018 Q3	$1.88M	Buy	19,838 +15,995	+416%	+$1.52M	1.07%	32
2018 Q2	$356K	Sell	3,843 -40	-1%	-$3.91K	0.2%	104
2018 Q1	$368K	Buy	3,883 +23	+0.6%	+$2.53K	0.21%	100
2017 Q4	$373K	Buy	3,860 +98	+3%	+$9.24K	0.21%	94
2017 Q3	$334K	Buy	3,762 +8	+0.2%	+$609	0.2%	93
2017 Q2	$272K	Buy	3,754 +9	+0.2%	+$605	0.17%	105
2017 Q1	$244K	Sell	3,745 -141	-4%	-$8.87K	0.17%	105
2016 Q4	$243K	Buy	3,886 +33	+0.9%	+$2.01K	0.2%	74
2016 Q3	$243K	Buy	3,853 +30	+0.8%	+$1.94K	0.23%	66
2016 Q2	$237K	Sell	3,823 -2,404	-39%	-$146K	0.25%	63
2016 Q1	$356K	Buy	+6,227	New	+$347K	0.36%	53

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Canal Capital Management's ABBV Position: Q2 2026 in Review

Canal Capital Management increased its AbbVie (ABBV) stake by 0.2% in Q2 2026, buying an estimated $2.15K and bringing the position to 4,890 shares worth $1.23M. The position accounts for 0.15% of the portfolio, ranked #91.

Canal Capital Management first reported a position in ABBV in Q1 2016 and has held it in 42 quarters since. The position peaked at $6.11M in Q3 2024. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Canal Capital Management held 4,890 shares of AbbVie worth $1.23M as of Q2 2026.
Canal Capital Management bought 10 AbbVie shares in Q2 2026, an estimated $2.15K.
AbbVie made up 0.15% of Canal Capital Management's portfolio in Q2 2026, its #91 holding.
Canal Capital Management first reported a position in AbbVie in Q1 2016 and has held it in 42 quarters since.
Canal Capital Management's AbbVie position peaked at $6.11M in Q3 2024.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Canal Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.